Available online on 15.01.2022 at http://jddtonline.info

Journal of Drug Delivery and Therapeutics

Open Access to Pharmaceutical and Medical Research

Open Access Full Text Article

Review Article

Analysis of animal models based on pre-clinical symptoms of gout

Yogendra Singh*[1], Pankaj Mishra[2] and Pushpendra Kannojia[1]

[1] *Department of Pharmacology, BIU College of Pharmacy, Bareilly International University, Bareilly-243006, Uttar Pradesh, India*

[2] *Department of Pharmaceutical Chemistry, Keshlata College of Pharmacy, Bareilly International University, Bareilly-243006, Uttar Pradesh, India*

Article Info:

Article History:

Received 13 November 2021
Reviewed 21 December 2021
Accepted 28 December 2021
Published 15 January 2022

Cite this article as:

Singh Y, Mishra P, Kannojia P, Analysis of animal models based on pre-clinical symptoms of gout, Journal of Drug Delivery and Therapeutics. 2022; 12(1):181-184

DOI: http://dx.doi.org/10.22270/jddt.v12i1.5270

*Address for Correspondence:

Mr. Yogendra Singh (Research Scholar), Department of Pharmacology, BIU College of Pharmacy, Bareilly International University, Bareilly-243006, Uttar Pradesh, India.

Abstract

Gout is a type of arthritis, which is a group of related disorders caused by episodes of abnormal inflammation in the joints. It is a metabolic disease characterized by high levels of uric acid in the blood. Uric acid is the end product of purine metabolism and hyperuricemia is caused by abnormalities of purine metabolism. Hyperuricemia is a risk factor for gout, heart disease, high blood pressure (hypertension), diabetes, and acute and chronic kidney disease. This research may attract widespread interest to researchers focusing on the different types of crystalline arthritis. There are over 100 types of arthritis. The most common forms are osteoarthritis (degenerative joint disease), rheumatoid arthritis, gout and pseudo-gout, septic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, still's disease etc.

Many animal models are available to get rid of gout, mainly the hyperuricemia animal model, monosodium urate air pouch gout model, Intra-articular gout in rat, Paw edema, Gouty Arthritis Model, and Gouty nephropathy model. Various investigations have created a reliable and economical animal model for arthritis in a relatively short brief timeframe, manifested by long-term gross and behavioral abnormalities along with intra-articular monosodium urate deposition and tophi formation.

Lately years, hyperuricemia disease has gradually increased in the world. There are many updates that can be made by taking the arthritis model. If such a situation prevails, then in a few years, the patients of gout can increase in great quantity and there is some treatment for this disease. In any case, further review is really needed to focus on its particular pathogenesis and drugs.

Keywords: Gout, Arthritis, Gout Animal Model, Inflammation, Hyperuricemia, monosodium urate, crystalline arthritis.

Introduction

Gout describes a group of metabolic disorders where crystals of sodium urate (the sodium salt of uric acid) deposit in joint fluid, cartilage, bones, tendons, bursas, or other sites. This happens from a blend of diet, other wellbeing issues, and hereditary components. This usually follows a prolonged period where uric acid levels in the blood are raised [1]. Gout is the most well-known type of fiery joint pain and is described by intense gout and constant gout with joint expanding and agony. Gout is of two main types of primary and secondary gout-

Primary gout

It is an inborn error of metabolism due to the high production of uric acid. This is mostly related to the increased synthesis of purine nucleotides.

Secondary gout

Secondary hyperuricemia is because of different infections causing increased synthesis or decreased discharge of uric acid (uric corrosive) [2].



Figure 1: Gout induce Rats

Gout

Gout is a painful deposition of uric corrosive gems in the synovial tissues of the body. Intense assaults normally show as a difficult monoarticular incendiary joint inflammation, traditionally of the first metatarsophalangeal joint, albeit different joints, just as the kidneys, might be influenced. A polyarticular presentation is more common with increasing age and length of the disease. Gout has been recognized since ancient times, with mentions by the Egyptians dating as early as 2640 BC.

In the fifth century BC, Hippocrates referred to gout as "theunwalkable disease." It has also been called "the disease of kings" due to the association with the intake of heavy foods and alcohol, apparently common in members of the ruling class [3].

Studies indicate that gout is the most prevalent form of arthritis observed in adults with an incidence rate of about 1.4%. There are numerous risk factors linked to the development of gout including genetics, gender, age, and diet [4]. Unlike other types of arthritis, the causative agent of gout is known and this knowledge has led to the development of valuable models for studying gout and the efficacy of test compounds for treatment.

Clinical Presentation and Management

Acute Gouty Arthritis

The intense period of gout is self-restricted and described by repetitive assaults of synovitis (articular aggravation) that present with torment, erythema, and expanding, most every now and again in the enormous toe yet different joints, ligaments, bursae, or different regions might be involved [5].

Chronic Gout

Although introductory scenes might be brief and uncommon, intense scenes might increment in recurrence and length after some time and lead to the improvement of persistent gout. Notwithstanding more incessant assaults, ongoing gout might be related to stores of uric corrosive precious stones known as tophi. Tophi might create in joints, ligaments, bone, and auricular or other cutaneous tissues. [6]

Figure 2: Acute and chronic gout

New Clinical Significance

However gout is frequently viewed as exclusively as far as its show as intense incendiary joint pain, it is genuinely a foundational illness with huge related metabolic comorbidities. Gout is connected to weight, hypertension, dyslipidemia, insulin obstruction, hyperglycemia, and coronary supply route sickness. Information from the National Health and Nutrition Examination Survey exhibited that metabolic condition was available in 62.8% of people with gout yet just 25.4% of those without gout. [7].

Importance of Animal Models

Animal models are basic for the improvement of medications and they frequently permit a forecast of the medication's latent capacity, which helps in foreseeing the monetary dangers for drug makers. Creature models are likewise being utilized to evaluate explicit issues like immunization conveyance, effective application or security, and harmfulness of antibody definitions, or individual parts thereof. As a rule, this is needed by administrative specialists, which regularly require the utilization of no less than two species to show security, much of the time little rodents. [8]

Hence, choosing the most proper animal model for the particular necessities of the exploration project is basic, and rather than being driven by minimal expense and simplicity of taking care of, scientists should search for models that intently take after the objective species and consequently produce results [9].

Animal Model

Hyperuricemia animal model

Hyperuricemia is a metabolic sickness brought about by a purine digestion issue and is portrayed by a serum urate level of more than 420 µmol/L in guys and 360 µmol/L in females. Hyperuricemia is a focal danger factor for gout and increments other constant illnesses, including cardiometabolic infection, kidney sickness, and hypertension [10]. Overproduction of uric corrosive is one of the fundamental drivers of hyperuricemia, and its improvement is contributed by dietary variables including fish, meat and drinking [11].

Gouty Arthritis Model

The Inflammatory mechanisms assume a significant part in the disease process of intense gouty joint pain. The aim of this study ware to determine the specifically expressed proteins through testing the proteins of the synovium in mice. The animal model of acute gouty arthritis were established by monosodium urate crystals combined with hypoxanthine [12].

Figure 3: Gouty Arthritis Rat

MSU air pouch gout model

In the Gout Air Pouch Model, infusion of monosodium urate crystals (MSU) into the air pocket initiates invasion and separation of cells related to the inflammation reaction and a simultaneous expansion in exudate volume. The two readouts are helpful and solid for the appraisal of compound viability - differential cell examination and exudate volume. MSU precious stones drive the provocative reaction by restricting a bunch of proteins from immunoglobulin to supplement [13]. The gem surface is a site of dynamic protein trade in which the make-up of the bound proteins mirrors the movement of the fiery reaction [11].

The improvement of an air pocket gives a pit in which the inflammatory reaction might be examined. The 7-day improvement of the air pocket prompts a pocket coating of granulation tissue comprising primarily of fibroblasts, macrophage, and pole cells, a surface morphologically like the synovium in joints and, hence, an amazing surface for the impacts of aggravation on the joints [14]. Monosodium urate incitement of the fiery course is related to the enactment of mononuclear phagocytes prompting a large group of proinflammatory go-betweens, for example, IL-1beta, TNF-alpha, IL-6, and IL-8 just as the enlistment of incendiary monocytes and neutrophils into the joint synovium. Histological assessment of the pocket lining is another important readout giving visual proof of a defensive impact of a test compound [7].

The histology incorporates a pathologist report. This is a discretionary thing the Client might choose to arrange later a survey of the fundamental review results-exudate volume and differential cell examination. In any monosodium urate, air pocket learns at WBI, the air pocket lining is gathered and saved at the end of the concentrate so these examples are accessible for histology [2].

Intra-articular gout in rat

In our Intra-articular Gout Model in Rat, monosodium urate gems are regulated into the knee joints by intra-articular (IA) infusion to straightforwardly trigger joint aggravation and enlarge normally for the infection. Male Wistar rodents are anesthetized and get intra-articular infusion to the knee. Aggravation tops on day 2 (MSU infusion on day 0). Assessment of test compound viability is dictated by estimation of knee joint width utilizing an advanced caliper, contrasted with vehicle and control bunches [15]. Serum can be collected for extra testing, like cytokine investigation. Knee tissue can likewise be gathered for histopathology or shipment to a customer [16].

As a further assessment of the sickness state and therapy viability, torment estimations can be joined into the review convention for reactions to mechanical (von Frey filaments) or warm (Hargreaves test) upgrades. World Biographical Index (WBI) likewise offers an IA Gout Model in rabbit in which female bunnies are anesthetized and get an intra-articular infusion to the knee. Knee irritation tops inside 12 hours of MSU infusion [17].

Paw edema

Infusion of carrageenan into the mouse paw delivered a biphasic edema. During the first stage, which created up to 24 h, edema was of low force and irrelevant to the dose of carrageenan given. During the second stage, later 24 h, edema was more articulated, introduced a reasonable portion reaction relationship, and topped at 72 h later infusion. Histological investigation of the sub plantar region 4 h later carrageenan infusion uncovered a diffuse cell invade with a transcendence of polymorphonuclear neutrophils [18].

Somewhere in the range of 48 and 72 h, an exceptional amassing of macrophages, eosinophil's and lymphocytes were noticed, along with an incredible expansion in the quantity of coursing leukocytes and platelets. Pretreatment with the anti-inflammatory drugs indomethacin and dexamethasone diminished the two periods of edema in a portion subordinate style. The current review shows that carrageenan-incited mouse paw edema comprises a new and intriguing model for the investigation of the middle people of irritation and for the screening of new mitigating drugs [19].



Figure 4: Paw edema

Gouty nephropathy model

The Gouty nephropathy model is mainly divided into two parts: acute nephropathy and chronic nephropathy. Acute gouty nephropathy is caused by uric acid crystals store in the tubules, usually collecting tubules. Chronic gouty nephropathy is primarily related to the deposition of crystals of monosodium urate in the marrow and is commonly seen in patients with gout, chronic hyperuricemia and hypertension [20].

Uric acid is the end product of purine metabolism that is not readily soluble in water, which is particularly evident in acidic environments in the distal nephrons of the kidney. Since humans do not have the uricase enzyme, an excess of it has the potential to damage the nephron and later kidney disease due to its high levels in the body [9]. Most cases of uric acid nephropathy are associated with chemotherapy treatment for cancer, which is associated with increased production of uric acid in the body. This condition is also more common in patients suffering from gout [4].

Uric acid nephropathy is usually asymptomatic with significantly reduced kidney function or failure. Symptoms may include low urine output, nausea, vomiting, lethargy, seizures, abdominal pain, painful urination and hematuria [6]. Uric acid nephropathy can be diagnosed based on the

presence of uric acid in joints, tissues, or bodily fluids. The urinalysis and Blood tests also help detect abnormal levels of uric acid in the blood. Treatment for uric acid nephropathy aims to relieve symptoms, reduce the risk of complications, and prevent the recurrence of symptoms [21].

Migration Inhibitory Factor (MIF) in Mouse Model of Gout

Mice are widely used to assess the pathogenesis of diseases. In an experimental model of gout, injection of uric acid crystals into the joints of rats caused inflammation and reprogramming of functional changes in the joints of rats [22]. MIF plays an important role in modulating arthritic inflammation, so extends valuable procedures to investigate uric acid crystal-induced joint inflammation in mice and to further understand the functions of MIF in gouty arthritis in vivo and in vitro give options [23].

Conclusion

The present study demonstrated for the first time, to the best of our knowledge, a novel herbal formula with multiple functions in nourishing kidneys and removing dampness, effectively prevented gouty arthritis in the MSU crystal-induced rat model, etc. In our review, we showed that MSU could actuate an expansion in the serum urate level in rodents and long haul hyperuricemia. Furthermore, long haul hyperuricemia additionally can possibly instigate gout and renal problems in our rodent models. Allopurinol and probenecid treatment additionally showed constructive outcomes in the hyperuricemia model rodents. Accordingly, building up a rodent model for hyperuricemia is appropriate and practical for additional hyperuricemia and gout research. Taking everything into account, advancement science and current clinical serum urate levels affirm the cozy connection among people and rodents in urate digestion.

References

1. Kang L, Miao MS, Liu HJ and Li N. Analysis of animal models based on clinical symptoms of gout. Zhongguo Zhongyao Zazhi. 2018; 43 (22):4547 - 4552.

2. Guan J, Huang XQ, Dong J Le, Lu HM, Lin YW, Liu M, Yi ZB, Wu LM, Huang YM and Lan T. A novel mouse model of hyperuricemia and gouty nephropathy. Chinese Medical Journal. 2020; 133(16):2012-2014. https://doi.org/10.1097/CM9.0000000000000964

3. Zhou M, Ze K, Hua L, Liu L, Kuai L, Zhang M, Li B, Wang Y and Li X. Cyr61 Promotes Inflammation of a Gouty Arthritis Model in Rats. Mediators Inflammation. 2020; 2020:1-13. https://doi.org/10.1155/2020/8298615

4. Zhu Y, Peng X and Ling G. An update on the animal models in hyperuricemia research. Clinical and experimental rheumatology. 2017; 35(5):860-864.

5. Gonzalez EB. An update on the pathology and clinical management of gouty arthritis. Clinical Rheumatol. 2012; 31(1):13-21. https://doi.org/10.1007/s10067-011-1877-0

6. Han J, Xie Y, Sui F, Liu C, Du X, Liu C, Fengx, Jiang D and Shenqi Z. decoction ameliorates monosodium urate crystal-induced gouty arthritis in rats through anti-inflammatory and anti-oxidative effects. Molecular Medicine Reports. 2016; 14(3):2589-2597. https://doi.org/10.3892/mmr.2016.5526

7. Hong F, Zheng A, Xu P, Wang J, Xue T, Dai S, Pan S, Guo Y, Xie X, Li L, Qiao X, Liu G and Zhai Y. High-protein diet induces hyperuricemia in a new animal model for studying human gout. International Journal of Molecular Sciences. 2020; 21(6):1 https://doi.org/10.3390/ijms21062147

8. Wu X, Wakamiya M, Vaishnav S, Geske R, Montgomery C, Jones P, Bradley A and Caskey T. Hyperuricemia and urate nephropathy in urate oxidase-deficient mice. Proceedings of the National Academy of Sciences. 1994; 91(2):742-746. https://doi.org/10.1073/pnas.91.2.742

9. Mandal AK and Mount DB. The molecular physiology of uric acid homeostasis. Annu. Rev. Physiol. 2015, 77:323-345. https://doi.org/10.1146/annurev-physiol-021113-170343

10. Fellstrom B, Danielson BG, Karlstrom B, Lithell H, Ljunghall, S and Vessby B. The influence of a high dietary intake of purine-rich animal protein on urinary urate excretion and supersaturation in renal stone disease. Clin. Sci. 1983, 64:399-405. https://doi.org/10.1042/cs0640399

11. Perez-Ruiz F, Calabozo M, Erauskin GG, Ruibal A and Herrero-Beites AM. Renal under excretion of uric acid is present in patients with apparent high urinary uric acid output. Arthritis Rheum. 2002, 47:610-613. https://doi.org/10.1002/art.10792

12. Kuo CF, Grainge MJ, Zhang W and Doherty M. Global epidemiology of gout: Prevalence, incidence and risk factors. Nat. Rev. Rheumatol. 2015, 11:649-662. https://doi.org/10.1038/nrrheum.2015.91

13. Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, Brown M, Choi H, Edwards NL and Janssens HJ. Gout classification criteria: American College of Rheumatology/European league against rheumatism collaborative initiative. Ann. Rheum. Dis. 2015, 74:1789-1798. https://doi.org/10.1136/annrheumdis-2015-208237

14. Martinon F, Petrilli V, Mayor A, Tardivel A and Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006; 440:237-241. https://doi.org/10.1038/nature04516

15. Anand PK and Kanneganti TD. NLRP6 in infection and inflammation. Microbes Infect. 2013; 15: 661-668. https://doi.org/10.1016/j.micinf.2013.06.009

16. Kramer HM, Curhan G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-1994. American Journal of Kidney Dis. 2002; 40(1):37-42. https://doi.org/10.1053/ajkd.2002.33911

17. Choi HK, Mount DB, Reginato AM. Pathogenesis of gout. Annals of Internal Medicine. 2005; 143(7):499-516. https://doi.org/10.7326/0003-4819-143-7-200510040-00009

18. Makarov SS, "NF-kappa B in rheumatoid arthritis: a pivotal regulator of inflammation, hyperplasia, and tissue destruction," Arthritis Research. 2001; 3(4)200-206. https://doi.org/10.1186/ar300

19. Kingsbury SR, Conaghan PG, and McDermott MF. "The role of the NLRP3 inflammasome in gout," Journal of Inflammation Research. 2011; 4:39-49. https://doi.org/10.2147/JIR.S11330

20. Hille R. "Molybdenum-containing hydroxylases". Archives of Biochemistry and Biophysics. 2005; 433(1):107-116. https://doi.org/10.1016/j.abb.2004.08.012

21. Singh D, Kumar V, and Singh C, "IFN- regulates xanthine oxidase-mediated iNOS-independent oxidative stress in maneb- and paraquat-treated rat polymorphonuclear leukocytes," Molecular and Cellular Biochemistry. 2017; 427(12):133-143. https://doi.org/10.1007/s11010-016-2905-9

22. Amat N, Umar A, Hoxur P, Anaydulla M, Imam G, Aziz R, Upur H, Kijjoa A & Moore N. "Traditional Uighur Medicine Karapxa decoction, inhibits liver xanthine oxidase and reduces serum uric acid concentrations in hyperuricemic mice and scavenges free radicals in vitro." BMC Complementary and Alternative Medicine. 2015; 15(1):131. https://doi.org/10.1186/s12906-015-0644-1

23. Lopez-Alarc C and Denicola A. "Evaluating the antioxidant capacity of natural products: a review on chemical and cellularbased assays," Analytica Chimica Acta. 2013; 763:1-10. https://doi.org/10.1016/j.aca.2012.11.051